The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

Childhood acute lymphoblastic leukemia (ALL) consists of various subtypes that respond differently to cytotoxic drugs and therefore have a markedly different clinical outcome. We used microarrays to investigate, in 190 children with ALL at initial diagnosis, whether 70 key apoptosis genes were differentially expressed between leukemic subgroups defined by lineage, genetic subtype, in vitro drug resistance, and clinical outcome. The expression of 44 of 70 genes was significantly different in T-versus B-lineage ALL, 22 genes differed in hyperdiploid versus nonhyperdiploid, 16 in TEL-AML1-positive versus-negative, and 13 in E2A-rearranged versus germ-line B-lineage ALL. Expression of MCL1 and DAPK1 was significantly associated with prednisolone sensitivity, whereas BCL2L13, HRK, and TNF were related to L-asparaginase resistance. BCL2L13 overexpression was also associated with unfavorable clinical outcome (P < .001). Multivariate analysis including known risk factors revealed that BCL2L13 expression was an independent prognostic factor (P = .011). The same trend was observed in a validation group of 92 children with ALL treated on a different protocol at St Jude (P = .051). In conclusion, ALL subtypes have a unique expression pattern of apoptosis genes and our data suggest that selective genes are linked to cellular drug resistance and prognosis in childhood B-lineage ALL.

[1]  Hiroshi Yasui,et al.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. , 2005, Blood.

[2]  R. Kim,et al.  Recent advances in understanding the cell death pathways activated by anticancer therapy , 2005, Cancer.

[3]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[4]  D. Coppola,et al.  Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells , 2005, Cancer biology & therapy.

[5]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[6]  T. Stankovic,et al.  Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. , 2004, Blood.

[7]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[8]  Peter Scheurich,et al.  NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP , 2004, The Journal of cell biology.

[9]  S. Knudsen,et al.  Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays , 2004, Leukemia.

[10]  M. D. Boer,et al.  In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype , 2004, Leukemia.

[11]  W. Kern,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[12]  M. D. Den Boer,et al.  Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. , 2003, Blood.

[13]  P. Hains,et al.  Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.

[14]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[15]  M. D. Boer,et al.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[17]  S. Armstrong,et al.  Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. , 2003, Blood.

[18]  Sho Hashimoto,et al.  APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line. , 2003, Biochemical and biophysical research communications.

[19]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[20]  M. D. Den Boer,et al.  Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. , 2003, Blood.

[21]  S. Armstrong,et al.  Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. , 2003, Blood.

[22]  Mian Wu,et al.  Bcl‐rambo beta, a special splicing variant with an insertion of an Alu‐like cassette, promotes etoposide‐ and Taxol‐induced cell death , 2003, FEBS letters.

[23]  T. Hongo,et al.  Two Groups of Philadelphia Chromosome—Positive Childhood Acute Lymphoblastic Leukemia Classified by Pretreatment Multidrug Sensitivity or Resistance in In Vitro Testing , 2002, International journal of hematology.

[24]  H. Findley,et al.  MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. , 2002, Blood.

[25]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[26]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[27]  M. Tomonaga,et al.  Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis , 2001, British journal of haematology.

[28]  F. Martinon,et al.  Bcl-rambo, a Novel Bcl-2 Homologue That Induces Apoptosis via Its Unique C-terminal Extension* , 2001, The Journal of Biological Chemistry.

[29]  J. Raemaekers,et al.  A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. , 2001, The Journal of molecular diagnostics : JMD.

[30]  Y. Lazebnik,et al.  Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. , 2000, Blood.

[31]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[32]  L. Corcos,et al.  Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies , 2000, Leukemia.

[33]  R. Pieters,et al.  TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.

[34]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[36]  S. Pollefeyt,et al.  Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. , 2000, Blood.

[37]  T. Hongo,et al.  Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. , 1999, International journal of hematology.

[38]  D. Nicholson,et al.  Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.

[39]  GS Salomons,et al.  Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome , 1999, Leukemia.

[40]  H. Stein,et al.  Three new types of Apaf-1 in mammalian cells. , 1999, Biochemical and biophysical research communications.

[41]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[42]  A. Hall,et al.  Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. , 1999, Blood.

[43]  D. Seol,et al.  A Caspase-9 Variant Missing the Catalytic Site Is an Endogenous Inhibitor of Apoptosis* , 1999, The Journal of Biological Chemistry.

[44]  C. Rudin,et al.  Signal transduction pathways that regulate cell survival and cell death , 1998, Oncogene.

[45]  M. D. Boer,et al.  Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.

[46]  F. Behm,et al.  Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. , 1998, Blood.

[47]  S. Srinivasula,et al.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.

[48]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[49]  N. Heerema,et al.  Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. , 1998, Blood.

[50]  J. Etxeberria,et al.  Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase‐3) expression in human leukemia cells , 1998, International journal of cancer.

[51]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[52]  Matthias Mann,et al.  FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC) , 1997, The EMBO journal.

[53]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[54]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[55]  H. Sather,et al.  Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.

[56]  W. Wilmanns,et al.  Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. , 1996, Leukemia.

[57]  R. Pieters,et al.  Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. , 1995, Leukemia & lymphoma.

[58]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[59]  R. Pieters,et al.  Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. , 1995, Blood.

[60]  R. Pieters,et al.  Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.

[61]  M. D’Incalci,et al.  Apoptosis Biochemical events and relevance to cancer chemotherapy , 1992, FEBS letters.

[62]  R. Pieters,et al.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[63]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[64]  Andy Greenfield,et al.  Using DNA microarrays. , 2008, Methods in molecular biology.

[65]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[66]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[67]  C. Willman.  Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.

[68]  T. Uchiyama,et al.  Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  G. Núñez,et al.  Expression and Functional Analysis of Apaf-1 Isoforms EXTRA WD-40 REPEAT IS REQUIRED FOR CYTOCHROME c BINDING AND REGULATED ACTIVATION OF PROCASPASE-9* , 2000 .

[70]  F. Behm,et al.  Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. , 1999, Blood.

[71]  R. Pieters,et al.  In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. , 1997, Blood.

[72]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[73]  S. Sen.  Biochemical events and relevance to cancer chemotherapy , 1992 .

[74]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .